Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

ASXL1 mutations are associated with adverse outcomes in european leukemianet (ELN) 2024 favorable risk patients with Acute Myeloid Leukemia (AML) treated with venetoclax (VEN) containing low-intensity therapy (LIT)

Blood (2025) 146 (Supplement 1): 3399.

https://doi.org/10.1182/blood-2025-3399

Published: 2025

Journal Articles

Characteristics and outcomes for patients with concomitant myeloproliferative neoplasms (MPN) and autoimmune disorders

Blood (2025) 146 (Supplement 1): 2037.

https://doi.org/10.1182/blood-2025-2037

Published: 2025

Journal Articles

Clonal persistence and early cooperative mutations shape transformation in myelofibrosis

Noushin Farnoud, Kamal Menghrajani, Paola Guglielmelli, Christopher Famulare, Erin McGovern, Giuseppe Gaetano Loscocco, Andriy Derkach, Andrew Dunbar, Naseema Gangat, Vikas Gupta, Andrea Arruda, Taghi Manshouri, Srdan Verstovsek, Andrew Kuykendall, Vincent Ho, Auro Viswabandya, Joachim Deeg, Thomas Monahan, Tania Jain, Jeanne Palmer, Alla Keyzner, Aaron Gerds, Alexandra Gomez-Arteaga, Nikolai Podoltsev, Roni Tamari, Helen Ajufo, Satyajit Kosuri, Haris Ali, Idoroenyi Amanam, Jordan Chervin, Minal Patel, Jesús Gutiérrez-Abril, Sarun Sereewattanawoot, Juan Arango Ossa, Francesco Passamonti, Francesco Maura, Maymona Abdelmagid, Ahmed Abdelrheem, Yassin Bashir, Muhammad Yousuf, Animesh Pardanani, Kapila Viges, David Shoultz, Rick Winneker, Omar Abdel-Wahab, John Mascarenhas, Ronald Hoffman, Ross Levine, Elli Papaemmanuil, Alessandro Vannucchi, Ayalew Tefferi, Raajit Rampal

Blood (2025) 146 (Supplement 1): 2046.

https://doi.org/10.1182/blood-2025-2046

Published: 2025

Journal Articles

Preclinical efficacy of dual BET/HAT inhibitor–based combinations against post myeloproliferative neoplasm secondary AML cells

Warren Fiskus, Christopher Mill, Lucia Masarova, Naveen Pemmaraju, Prithviraj Bose, Arnav Gupta, Hanxi Hou, Taghi Manshouri, Jayastu Senapati, Sanam Loghavi, Andrew Dunbar, Claes Wahlestedt, Courtney DiNardo, Kapil Bhalla

Blood (2025) 146 (Supplement 1): 5053.

https://doi.org/10.1182/blood-2025-5053

Published: 2025

Journal Articles

EP31670, a dual-BET + p300 inhibitor, demonstrates pre-clinical efficacy, including in combination with JAK inhibition, in the hMPLW515L adoptive transfer model of myelofibrosis (MF)

Linda Fabris, Warren Fiskus, Kavi O'Connor, Zachary Zaroogian, Shishir Waghray, Gautam Borthakur, Prithviraj Bose, Naveen Pemmaraju, Lucia Masarova, Taghi Manshouri, Kapil Bhalla, Claes Wahlestedt, Ross Levine, Andrew Dunbar

Blood (2025) 146 (Supplement 1): 3759.

https://doi.org/10.1182/blood-2025-3759

Published: 2025

Journal Articles

AJ1-11095, a potent and highly selective type-II JAK2 inhibitor, shows enhanced therapeutic efficacy as compared with type-I JAK2 inhibitor ruxolitinib in models of myeloproliferative neoplasms (MPNs)

Marc Usart, Shivam Rai, Kavi O'Connor, Quentin Kimmerlin, Zachary Zaroogian, Matthew Wereski, Charlie Xu, Craig Masse, Stevan Hubbard, Ross Levine, Maria Kleppe, Radek Skoda, Andrew Dunbar

Blood (2025) 146 (Supplement 1): 1983.

https://doi.org/10.1182/blood-2025-1983

Published: 2025

Journal Articles

Quantitative profiling and clinical correlative analysis of fibrocytes and mesenchymal stromal cells in myelofibrosis spleen

Ivo Veletic, Taghi Manshouri, Christopher Pacheco, Christopher Ly, C. Cameron Yin, Jared Burks, Naveen Pemmaraju, Lucia Masarova, Prithviraj Bose, Hussein Abbas, Andrew Dunbar

Blood (2025) 146 (Supplement 1): 5542.

https://doi.org/10.1182/blood-2025-5542

Published: 2025

Journal Articles

Preclinical efficacy of CDK7 inhibitor–based combinations against myeloproliferative neoplasms transformed to AML

Blood (2025) 145 (6): 612–624.

https://doi.org/10.1182/blood.2024026388

Published: 2025

Includes: Supplemental data

Journal Articles

TMPRSS6 Antisense Oligonucleotide Therapy Reverses Inflammation in Jak2 V617F Mutant Mice

Maayan Levy, Huihui Li, Andrew Dunbar, Zixing Huang, Young Park, Min Lu, Pinanong Na Phattalung, Marina Planoutene, Carla Casu, Stefano Rivella, Shuling Guo, Ross L Levine, Ronald Hoffman, Yelena Ginzburg

Blood (2024) 144 (Supplement 1): 8.

https://doi.org/10.1182/blood-2024-203806

Published: 2024

Journal Articles

Temporal Dynamics of Bone Marrow Fibrocytes in the Progression of Primary Myelofibrosis

Ivo Veletic, Taghi Manshouri, C. Cameron Yin, Christopher D. Pacheco, Christopher P. Ly, Enes Dasdemir, Evan N. Cohen, Lucia Masarova, Naveen Pemmaraju, Prithviraj Bose, Hagop M. Kantarjian, Zeev Estrov, Patrick K. Reville, Andrew Dunbar, Hussein A. Abbas

Blood (2024) 144 (Supplement 1): 1760.

https://doi.org/10.1182/blood-2024-211966

Published: 2024

Journal Articles

The Second Generation Type II JAK2 Inhibitor, AJ1-10502, Demonstrates Enhanced Selectivity, Improved Therapeutic Efficacy and Reduced Mutant Cell Fraction Compared to Type I JAK2 Inhibitors in Models of Myeloproliferative Neoplasms (MPNs)

Shivam Rai, Jan Stetka, MARC Usart, Hui Hao-Shen, Young Park, Remie Houston, Anthony R. Martinez Benitez, Matthew Wereski, Emily Guzzardi, Sonali Persaud, Hailey Ramzan, Alan Futran, Charley Xu, Jeremy Greenwood, Sayan Mondal, Craig Masse, Ross L. Levine, Radek C. Skoda, Andrew Dunbar

Blood (2022) 140 (Supplement 1): 6722–6723.

https://doi.org/10.1182/blood-2022-162621

Published: 2022

Journal Articles

Jak2 V617F Reversible Activation Shows an Essential Requirement for Jak2 V617F in Myeloproliferative Neoplasms (MPNs)

Blood (2022) 140 (Supplement 1): 803–804.

https://doi.org/10.1182/blood-2022-164827

Published: 2022

Journal Articles

A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2 -Mutant AML Patients: 3-Year Follow-up

Blood (2022) 140 (Supplement 1): 2016–2019.

https://doi.org/10.1182/blood-2022-166850

Published: 2022

Journal Articles

Germline Runx1 Mutations Induce Inflammation in Hematopoietic Stem and Progenitor Cells and Predispose to Hematologic Malignancies

Mohd Hafiz Ahmad, Mahesh Hegde, Waihay J. Wong, Andrew Dunbar, Anneliese Carrascoso, Lisa J Garrett, Nayara K Ferreira, Haibo Liu, Rui Li, Benjamin L. Ebert, Ross L. Levine, Julie Zhu, Scot A. Wolfe, Paul P Lui, Lucio H. Castilla

Blood (2021) 138 (Supplement 1): 2201.

https://doi.org/10.1182/blood-2021-153433

Published: 2021

Journal Articles

“Interferon” with MPN hematopoietic stem cells

Andrew Dunbar, Ross L. Levine

Blood (2021) 137 (16): 2129–2130.

https://doi.org/10.1182/blood.2021011273

Published: 2021

Journal Articles

Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors

Blood (2021) 137 (15): 2103–2113.

https://doi.org/10.1182/blood.2020007488

Published: 2021

Includes: Supplemental data

Journal Articles

Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 18–20.

https://doi.org/10.1182/blood-2020-137552

Published: 2020

Journal Articles

Machine Learning for Prediction of Cancer-Associated Venous Thromboembolism

Simon Mantha, MDMPH, Andrew Dunbar, MD, Kelly L. Bolton, MD PhD, Sean Devlin, PhD, Dmitriy Gorenshteyn, PhD, Mark Donoghue, PhD, Maria E. Arcila, MD, Gerald A. Soff, MD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-138579

Published: 2020

Journal Articles

Increased Interleukin-8 (IL8)-CXCR2 Signaling Promotes Progression of Bone Marrow Fibrosis in Myeloproliferative Neoplasms

Andrew Dunbar, MD, Min Lu, PhDMD, Mirko Farina, MD, Young Park, BS, Julie Yang, PhD, Dongjoo Kim, PhD, Abdul Karzai, BS, Mohamed E Salama, MD, Jenna Snyder, BS, Aishwarya Krishnan, BS, Richard P. Koche, PhD, Rong Fan, PhD, Ross L. Levine, MD, Ronald Hoffman, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-138843

Published: 2020

Journal Articles

Extended Mutational Profiling By MSK-IMPACT TM Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy

Andrew Dunbar, MD, Kelly Bolton, MD PhD, Sean M. Devlin, PhD, Francisco Sanchez-Vega, PhD, Jianjiong Gao, PhD, Jodi V. Mones, MD, Jonathan M. Wills, BA, Daniel Kelly, MS, Mirko Farina, MD, Sirish Kishore, MD, Krishna Juluru, MD, Neil Iyengar, MD, David M. Hyman, MD, Ahmet Zehir, PhD, Wungki Park, MD, Alok A Khorana, MD, Gerald A. Soff, MD, Simon Mantha, MDMPH

Blood (2019) 134 (Supplement_1): 633.

https://doi.org/10.1182/blood-2019-124242

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

ASXL1 mutations are associated with adverse outcomes in european leukemianet (ELN) 2024 favorable risk patients with Acute Myeloid Leukemia (AML) treated with venetoclax (VEN) containing low-intensity therapy (LIT)

Characteristics and outcomes for patients with concomitant myeloproliferative neoplasms (MPN) and autoimmune disorders

Clonal persistence and early cooperative mutations shape transformation in myelofibrosis

Preclinical efficacy of dual BET/HAT inhibitor–based combinations against post myeloproliferative neoplasm secondary AML cells

EP31670, a dual-BET + p300 inhibitor, demonstrates pre-clinical efficacy, including in combination with JAK inhibition, in the hMPLW515L adoptive transfer model of myelofibrosis (MF)

AJ1-11095, a potent and highly selective type-II JAK2 inhibitor, shows enhanced therapeutic efficacy as compared with type-I JAK2 inhibitor ruxolitinib in models of myeloproliferative neoplasms (MPNs)

Quantitative profiling and clinical correlative analysis of fibrocytes and mesenchymal stromal cells in myelofibrosis spleen

Preclinical efficacy of CDK7 inhibitor–based combinations against myeloproliferative neoplasms transformed to AML

TMPRSS6 Antisense Oligonucleotide Therapy Reverses Inflammation in Jak2 V617F Mutant Mice

Temporal Dynamics of Bone Marrow Fibrocytes in the Progression of Primary Myelofibrosis

The Second Generation Type II JAK2 Inhibitor, AJ1-10502, Demonstrates Enhanced Selectivity, Improved Therapeutic Efficacy and Reduced Mutant Cell Fraction Compared to Type I JAK2 Inhibitors in Models of Myeloproliferative Neoplasms (MPNs)

Jak2 V617F Reversible Activation Shows an Essential Requirement for Jak2 V617F in Myeloproliferative Neoplasms (MPNs)

A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2 -Mutant AML Patients: 3-Year Follow-up

Germline Runx1 Mutations Induce Inflammation in Hematopoietic Stem and Progenitor Cells and Predispose to Hematologic Malignancies

“Interferon” with MPN hematopoietic stem cells

Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors

Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Machine Learning for Prediction of Cancer-Associated Venous Thromboembolism

Increased Interleukin-8 (IL8)-CXCR2 Signaling Promotes Progression of Bone Marrow Fibrosis in Myeloproliferative Neoplasms

Extended Mutational Profiling By MSK-IMPACT TM Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only